Behavioral effects of cannabinoid agents in animals

Critical Reviews in Neurobiology

Volumn 13, Issue 3, 1999, Pages 243-281

  Chaperon, Frédérique ^a,b   Thiébot, Marie Hélène ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Animal behavior; Cognition; Dependence; Feeding behavior; Motivational processes; Motor activity; Pain; Tolerance

Indexed keywords

ACETYLCHOLINE; ANANDAMIDE; CANNABINOID; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABIS; DOPAMINE; OPIATE; RECEPTOR SUBTYPE; RIMONABANT;

ANALGESIA; ANIMAL BEHAVIOR; ANXIETY; APPETITE; ARTICLE; CATALEPSY; COGNITION; FEEDING BEHAVIOR; GABAERGIC SYSTEM; HYPOTHERMIA; IMMUNE RESPONSE; MEMORY; MOTIVATION; NEUROBIOLOGY; NOCICEPTION; NONHUMAN; VOMITING;

EID: 1642602474     PISSN: 08920915     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevNeurobiol.v13.i3.20     Document Type: Article

References (283)

1. Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., and Bonner, T. I., Structure of a cannabinoid receptor and functional expression of the cloned cDNA, Nature, 346, 561-564, 1990.
2. Munro, S., Thomas, K. L., and Abu-Shaar, M., Molecular characterization of a peripheral receptor for cannabinoids, Nature, 365, 61-65, 1993.
3. Haney, M., Comer, S. D., Ward, A. S., Foltin, R. W., and Fischman, M. W., Factors influencing marijuana self-administration by humans, Behav. Pharmacol., 8, 101-112, 1997.
4. Hollister, L., Health aspects of cannabis, Pharmacol. Rev., 38, 1-20, 1986.
5. Adams, I. B. and Martin, B. R., Cannabis: pharmacology and toxicology in animals and humans, Addiction, 91, 1585-1614, 1996.
6. Dewey, W., Cannabinoid pharmacology, Pharmacol. Rev., 38, 151-178, 1986.
7. 9-THC and cannabinoid (CB1) receptor gene expression in mice, Behav. Brain Res., 72, 115-125, 1996.
8. Onaivi, E. S., Green, M. R., and Martin, B. R., Pharmacological characterization of cannabinoids in the elevated plus maze, J. Pharmacol. Exp. Ther., 253, 1002-1009, 1990.
9. 1-like cannabinoid receptors, J. Pharmacol. Exp. Ther., 281, 1030-1037, 1997.
10. 9-tetrahydrocannabinol on complex behavior of squirrel monkeys, Psychopharmacology, 71, 247-256, 1980.
11. Razdan, R. K., Structure-activity relationships in cannabinoids, Pharmacol. Rev., 38, 75-149, 1986.
12. Lichtman, A. H., Wiley, J. L., LaVecchia, K. L., Neviaser, S. T., Arthur, D. B., Wilson, D. M., and Martin, B. R., Effects of SR 141716A after acute and chronic cannabinoid administration in dogs, Eur. J. Pharmacol., 357, 139-148, 1998.
13. Howlett, A. C., The CB1 cannabinoid receptor in the brain, Neurobiol. Dis., 5, 405-416, 1998.
14. 1 receptors on peripheral sympathetic nerves, Br. J. Pharmacol., 118, 2023-2028, 1996.
15. Pertwee, R. G., Pharmacology of cannabinoid CB1 and CB2 receptors, Pharmacol. Ther., 74, 129-180, 1997.
16. Galiègue, S., Mary, S., Marchand, J., Dussossoy, D., Carrière, D., Carayon, P., Bouaboula, M., Shire, D., Le Fur, G., and Casellas, P., Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations, Eur. J. Biochem., 232, 54-61, 1995.
17. Daaka, Y., Friedman, H., and Klein, T. W., Cannabinoid receptor proteins are increased in Jurkat, human T-cell line after mitogen activation, J. Pharmacol. Exp. Ther., 276, 776-783, 1996.
18. Herkenham, M., Lynn, A. B., Johnson, M. R., Melvin, L. S., de Costa, B. R., and Rice, K. C., Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study, J. Neurosci., 11, 563-583, 1991.
19. Mailleux, P. and Vanderhaeghen, J. J., Distribution of neural cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry, Neuroscience, 48, 655-668, 1992.
20. Tsou, K., Brown, S., Sañudo-Peña, M. C., Mackie, K., and Walker, J. M., Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system, Neuroscience, 83, 393-411, 1998.
21. Glass, M., Dragunow, M., and Faull, R. L. M., Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal, and adult human brain, Neuroscience, 77, 299-318, 1997.
22. Rinaldi-Carmona, M., Calandra, B., Shire, D., Bouaboula, M., Oustric, D., Barth, F., Casellas, P., Ferrara, P., and Le Fur, G., Characterization of two cloned human CB1 cannabinoid receptor isoforms, J. Pharmacol. Exp. Ther., 278, 871-878, 1996.
23. Shire, D., Carillon, C., Kaghad, M., Calandra, B., Rinaldi-Carmona, M., Le Fur, G., Caput, D., and Ferrara, P., An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing, J. Biol. Chem., 270, 3726-3731, 1995.
24. Mackie, K. and Hille, B., Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells, Proc. Natl. Acad. Sci. U.S.A., 89, 3825-3829, 1992.
25. Felder, C. C., Briley, E. M., Axelrod, J., Simpson, J. T., Mackie, K., and Devane, W. A., Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction, Proc. Natl. Acad. Sci. U.S.A., 90, 7656-7660, 1993.
26. Bouaboula, M., Poinot-Chazel, C., Bourrié, B., Calandra, B., Rinaldi-Carmona, M., Le Fur, G., and Casellas, P., Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1, Biochem. J., 312, 637-641, 1995.
27. Gifford, A. N., Bruneus, M., Gatley, S. J., Lan, R., Makriyannis, A., and Volkow, N. D., Large receptor reserve for cannabinoid actions in the central nervous system, J. Pharmacol. Exp. Ther., 288, 478-483, 1999.
28. Deadwyler, S. A., Hampson, R. E., Mu, J., Whyte, A., and Childers, S., Cannabinoids modulate voltage sensitive potassium A-current in hippocampal neurons via a cAMP-dependent process, J. Pharmacol. Exp. Ther., 273, 734-743, 1995.
29. 3 receptors in rat nodose ganglion neurons, J. Neurophysiol., 73, 907-910, 1995.
30. Turkanis, S. A., Partlow, L. M., and Karler, R., Delta-9-tetrahydrocannabinol depresses inward sodium current in mouse neuroblastoma cells, Neuropharmacology, 30, 73-77, 1991.
31. Bouaboula, M., Poinot-Chazel, C., Marchand, J., Canat, X., Bourrié, B., Rinaldi-Carmona, M., Calandra, B., Le Fur, G., and Casellas, P., Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression, Eur. J. Biochem., 237, 704-711, 1996.
32. Barth, F., Cannabinoid receptor agonists and antagonists, Expert Opin. Ther. Pat., 8, 301-313, 1998.
33. 9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors, Life Sci., 63, PL1-PL6, 1998.
34. Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., Pertwee, R., Griffin, G., Bayewitch, M., Barg, J., and Vogel, Z., Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors, Biochem. Pharmacol., 50, 83-90, 1995.
35. Devane, W. A., Hanus, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., and Mechoulam, R., Isolation and structure of a brain constituent that binds to the cannabinoid receptor, Science, 258, 1946-1949, 1992.
36. Mechoulam, R., Fride, E., and Di Marzo, V., Endocannabinoids, Eur. J. Pharmacol., 359, 1-18, 1998.
37. Mechoulam, R. and Ben-Shabat, S., From gan-zi-gun-nu to anandamide and 2-arachidonoylglycerol: the ongoing story of cannabis, Nat. Prod. Rep., 16, 131-143, 1999.
38. Hillard, C. J. and Campbell, W. B., Biochemistry and pharmacology of arachidonylethanolamide, a putative endogenous cannabinoid, J. Lipid Res., 38, 2383-2398, 1997.
39. Smith, P. B., Compton, D. R., Welch, S. P., Razdan, R. K., Mechoulam, R., and Martin, B. R., The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice, J. Pharmacol. Exp. Ther., 270, 219-227, 1994.
40. Childers, S. R. and Breivogel, C. S., Cannabis and endogenous cannabinoid systems, Drug Alcohol Depend., 51, 173-187, 1998.
41. Berrendero, F., Sepe, N., Ramos, J. A., Di Marzo, V., and Fernàndez-Ruiz, J. J., Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestational and early postnatal period, Synapse, 33, 181-191, 1999.
42. Ben-Shabat, S., Fride, E., Sheskin, T., Tamiri, T., Rhee, M. H., Vogel, Z., Bisogno, T., De Petrocellis, L., Di Marzo, V., and Mechoulam, R., An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity, Eur. J. Pharmacol., 353, 23-31, 1998.
43. Mechoulam, R., Fride, E., Hanus, L., Sheskin, T., Bisogno, T., Di Marzo, V., Bayewitch, M., and Vogel, Z., Anandamide may mediate sleep induction, Nature, 389, 25-26, 1997.
44. Rinaldi-Carmona, M., Barth, F., Héaulme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Néliat, G., Caput, D., Ferrara, P., Soubrié, P., Brelière, J. C., and Le Fur, G., SR 141716A, a potent and selective antagonist of the brain cannabinoid receptor, FEBS Lett., 350, 240-244, 1994.
45. Rinaldi-Carmona, M., Barth, F., Millan, J., Derocq, J., Casellas, P., Congy, C., Oustric, D., Sarran, M., Bouaboula, M., Calandra, B., Portier, M., Shire, D., Brelière, J. C., and Le Fur, G., SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor, J. Pharmacol. Exp. Ther., 284, 644-650, 1998.
46. Khanolkar, A. D., Abadji, V., Lin, S., Hill, W. A. G., Taha, G., Abouzid, K., Meng, Z., Fan, P., and Makriyannis, A., Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand, J. Med. Chem., 39, 4515-4519, 1996.
47. 2 receptor, J. Med. Chem., 39, 3875-3877, 1996.
48. Showalter, V. M., Compton, D. R., Martin, B. R., and Abood, M. E., Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): Identification of cannabinoid receptor subtype selective ligands, J. Pharmacol. Exp. Ther., 278, 989-999, 1996.
49. Felder, C. C., Joyce, K. E., Briley, E. M., Glass, M., Mackie, K. P., Fahey, K. J., Cullinan, G. J., Hunden, D. C., Johnson, D. W., Chaney, M. O., Koppel, G. A., and Brownstein, M., LY 320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation, J. Pharmacol. Exp. Ther., 284, 291-297, 1998.
50. Gallant, M., Dufresne, C., Gareau, Y., Guay, D., Leblanc, Y., Prasit, P., Rochette, C., Sawyer, N., Slipetz, D. M., Tremblay, N., Metters, K. M., and Labelle, M., New class of potent ligands for the human peripheral cannabinoid receptor, Bioorg. Med. Chem. Lett., 6, 2263-2268, 1996.
51. Gareau, Y., Dufresne, C., Gallant, M., Rochette, C., Sawyer, N., Slipetz, D. M., Tremblay, N., Weech, P. K., Metters, K. M., and Labelle, M., Structure activity relationships of tetrahydrocannabinol analogues on human cannabinoid receptors, Bioorg. Med. Chem. Lett., 6, 189-194, 1996.
52. Martin, B. R. and Lichtman, A. H., Cannabinoid transmission and pain perception, Neurobiol. Dis., 5, 447-461, 1998.
53. Lichtman, A. H. and Martin, B. R., The selective cannabinoid antagonist SR 141716A blocks cannabinoid-induced antinociception in rats, Pharmacol. Biochem. Behav., 57, 7-12, 1997.
54. Martin, W. J., Tsou, K., and Walker, J. M., Cannabinoid receptor-mediated inhibition of the rat tail-flick reflex after microinjection into the rostral ventromedial medulla, Neurosci. Lett., 242, 33-36, 1998.
55. Martin, W. J., Patrick, S. L., Coffin, P. O., Tsou, K., and Walker, J. M., An examination of the central sites of action of cannabinoid-induced antinociception in the rat, Life Sci., 56, 2103-2109, 1995.
56. Welch, S. P. and Stevens, D. L., Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice, J. Pharmacol. Exp. Ther., 262, 10-18, 1992.
57. Rubino, T., Tizzoni, L., Viganò, D., Massi, P., and Parolaro, D., Modulation of rat brain cannabinoid receptors after chronic morphine treatment, NeuroReport, 8, 3219-3223, 1997.
58. Vivian, J. A., Kishioka, S., Butelman, E. R., Broadbear, J., Lee, K. O., and Woods, J. H., Analgesic, respiratory and heart rate effects of cannabinoid and opioid agonists in rhesus monkeys: Antagonist effects of SR 141716A, J. Pharmacol. Exp. Ther., 286, 697-703, 1998.
59. Herzberg, U., Eliav, E., Bennett, G. J., and Kopin, I. J., The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high-affinity cannabinoid agonist, in a rat model of neuropathic pain, Neurosci. Lett., 221, 157-160, 1997.
60. 9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats, Pharmacol. Biochem. Behav., 60, 183-191, 1998.
61. 9-THC-induced antinociception, J. Pharmacol. Exp. Ther., 273, 1235-1244, 1995.
62. 9-tetrahydrocannabinol as measured with the formalin test, Eur. J. Pharmacol., 61, 313-315, 1980.
63. 9-tetrahydrocannabinol-induced responses and apparent agonist activity, J. Pharmacol. Exp. Ther., 277, 586-594, 1996.
64. Welch, S. P., Huffman, J. W., and Lowe, J., Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR 141716A, J. Pharmacol. Exp. Ther., 286, 1301-1308, 1998.
65. 1 receptor knockout mice, Science, 283, 401-404, 1999.
66. Zimmer, A., Zimmer, A. M., Hohmann, A. G., Herkenham, M., and Bonner, T. I., Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice, Proc. Natl. Acad. Sci. U.S.A., 96, 5780-5785, 1999.
67. Edsall, S. A., Knapp, R. J., Vanderah, T. W., Roeske, W. R., Consroe, P., and Yamamura, H. I., Antisense oligodeoxynucleotide treatment to the brain cannabinoid receptor inhibits antinociception, NeuroReport, 1, 593-596, 1996.
68. Durnett Richardson, J., Aanonsen, L., and Hargreaves, K. M., SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice, Eur. J. Pharmacol., 319, R3-R4, 1997.
69. Meng, I. D., Manning, B. H., Martin, W. J., and Fields, H. L., An analgesia circuit activated by cannabinoids, Nature, 395, 381-383, 1998.
70. Strangman, N. M., Patrick, S. L., Hohmann, A. G., Tsou, K., and Waker, J. M., Evidence for a role of endogenous cannabinoids in the modulation of acute and tonic pain sensitivity, Brain Res., 813, 323-328, 1998.
71. Welch, S. P., Thomas, C., and Patrick, G. S., Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine, J. Pharmacol. Exp. Ther., 272, 310-321, 1995.
72. Welch, S. P., Blockade of cannabinoid-induced antinociception by norbinaltorphimine, but not N,N-diallyl-tyrosine-aib-phenylalanine-leucine, ICI 174,864 or naloxone in mice, J. Pharmacol. Exp. Ther., 265, 633-640, 1993.
73. 9-tetrahydrocannabinol-induced analgesia in mice, Eur. J. Pharmacol., 301, 75-81, 1996.
74. 9-THC in the spinal cord, Brain Res., 689, 157-158, 1995.
75. 9-tetrahydrocannabinol-induced analgesia by morphine in mice: involvement of μ-and κ-opioid receptors, Eur. J. Pharmacol., 318, 11-16, 1996.
76. 9-tetrahydrocannabinol, Pharmacol. Biochem. Behav., 60, 559-566, 1998.
77. 9-tetrahydrocannabinol and morphine in the spinal cord, J. Pharmacol. Exp. Ther., 279, 608-616, 1996.
78. 9-tetrahydrocannabinol in mice, Eur. J. Pharmacol., 260, 5-13, 1994.
79. 9-tetrahydrocannabinol and kappa opioids in mice, J. Pharmacol. Exp. Ther., 268, 1381-1387, 1994.
80. Vaysse, P. J. J., Gardner, E. L., and Zukin, R. S., Modulation of rat brain opioid receptors by cannabinoids, J. Pharmacol. Exp. Ther., 241, 534-539, 1987.
81. Mansour, A., Khachaturian, H., Lewis, M. E., Akil, H., and Watson, S. J., Anatomy of CNS opioid receptors, Trends Neurosci., 11, 308-314, 1988.
82. Adams, I. B., Compton, D. R., and Martin, B. R., Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain, J. Pharmacol. Exp. Ther., 284, 1209-1217, 1998.
83. Compton, D. R. and Martin, B. R., The effects of the enzyme inhibitor phenylmethylsulfonyl fluoride on the pharmacological effect of anandamide in the mouse model of cannabimimetic activity, J. Pharmacol. Exp. Ther., 283, 1138-1143, 1997.
84. Stein, E. A., Fuller, S. A., Edgemond, W. S., and Campbell, W. B., Physiological and behavioral effects of the endogenous cannabinoid, arachidonylethanolamide (anandamide), in the rat, Br. J. Pharmacol., 119, 107-114, 1996.
85. Sulcova, A., Mechoulam, R., and Fride, E., Biphasic effects of anandamide, Pharmacol. Biochem. Behav., 59, 347-352, 1998.
86. 9-tetrahydrocannabinol, J. Pharmacol. Exp. Ther., 272, 699-707, 1995.
87. Anderson, J. J., Kask, A. M., and Chase, T. N., Effects of cannabinoid receptor stimulation and blockade on catalepsy produced by dopamine receptor antagonists, Eur. J. Pharmacol., 295, 163-168, 1996.
88. McGregor, I. S., Issakidis, C. N., and Prior, G., Aversive effects of the synthetic cannabinoid CP 55,940 in rats, Pharmacol. Biochem. Behav., 53, 657-664, 1996.
89. Crawley, J. N., Corwin, R. L., Robinson, J. K., Felder, C. C., Devane, W. A., and Alxelrod, J., Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents, Pharmacol. Biochem. Behav., 46, 967-972, 1993.
90. Järbe, T. U. C., Sheppard, R., Lamb, R. J., Makriyannis, A., Lin, S., and Goutopoulos, A., Effects of delta-9-tetrahydrocannabinol and (R)-methanandamide on open-field behavior in rats, Behav. Pharmacol., 9, 169-174, 1998.
91. 9-Tetrahydrocannabinol, but not the endogenous cannabinoid receptor ligand anandamide, produces conditioned place avoidance, Life Sci., 62, 2431-2439, 1998.
92. Arnold, J. C., Topple, A. N., Hunt, G. E., and McGregor, I. S., Effects of pre-exposure and co-administration of the cannabinoid receptor agonist CP 55,940 on behavioral sensitization to cocaine, Eur. J. Pharmacol., 354, 9-16, 1998.
93. 37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats, J. Pharmacol. Exp. Ther., 276, 56-64, 1996.
94. Fride, E. and Mechoulam, R., Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent, Eur. J. Pharmacol., 231, 313-314, 1993.
95. Ferrari, F., Ottani, A., and Giuliani, D., Cannabimimetic activity in rats and pigeons of HU-210, a potent antiemetic drug, Pharmacol. Biochem. Behav., 62, 75-80, 1999.
96. Gough, A. L. and Olley, J. E., Catalepsy-induced by intrastriatal injections of delta-9-THC and 11-OH-delta-9-THC in the rat, Neuropharmacology, 17, 137-144, 1978.
97. Carriero, C., Aberman, J., Lin, S. Y., Hill, A., Makriyannis, A., and Salamone, J. D., A detailed characterization of the effects of four cannabinoid agonists on operant pressing, Psychopharmacology, 137, 147-156, 1998.
98. Glass, M., Brotchie, J. M., and Maneuf, Y. P., Modulation of neurotransmission by cannabinoids in the basal ganglia, Eur. J. Neurosci., 9, 199-203, 1998.
99. Miller, A. S. and Walker, J. M., Electrophysiological effects of a cannabinoid on neural activity in the globus pallidus, Eur. J. Pharmacol., 304, 29-35, 1996.
100. Cadogan, A. K., Alexander, S. P. H., Boyd, E. A., and Kendall, D. A., Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum, J. Neurochem., 69, 1131-1137, 1997.
101. Romero, J., García, L., Cebeira, M., Zadrozny, D., Fernández-Ruiz, J. J., and Ramos, J. A., The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behavior: role of nigrostriatal dopaminergic neurons, Life Sci., 56, 2033-2040, 1995.
102. Castañeda, E., Moss, D. E., Oddie, S. D., and Whishaw, I. Q., THC does not affect striatal dopamine release: microdialysis in freely moving rats, Pharmacol. Biochem. Behav., 40, 587-591, 1991.
103. 9-tetrahydrocannabinol: possible involvement of nigrostriatal dopaminergic alterations, Pharmacol. Biochem. Behav., 45, 291-298, 1993.
104. Giuffrida, A., Parsons, L. H., Kerr, T. M., Rodríguez de Fonseca, F., Navarro, M., and Piomelli, D., Dopamine activation of endogenous cannabinoid signaling in dorsal striatum, Nat. Neurosci., 2, 358-363, 1999.
105. Pertwee, R. G. and Wickens, A. P., Enhancement by chlordiazepoxide of catalepsy induced in rats by intravenous or intrapallidal injections of enantiomeric cannabinoids, Neuropharmacology, 30, 237-244, 1991.
106. Herkenham, M., Lynn, A. B., de Costa, B. R., and Richfield, E. K., Neuronal localization of cannabinoid receptors in the basal ganglia of the rat, Brain Res., 547, 267-274, 1991.
107. Romero, J., de Miguel, R., Ramos, J. A., and Fernández-Ruiz, J. J., The activation of cannabinoid receptors in striatonigral GABAergic neurons inhibited GABA uptake, Life Sci., 62, 351-363, 1998.
108. 9-tetrahydrocannabinol reduces γ-aminobutyric acid uptake in the globus pallidus, Eur. J. Pharmacol., 308, 161-164, 1996.
109. B receptors in the motor inhibition produced by agonists of brain cannabinoid receptors, Behav. Pharmacol., 7, 299-302, 1996.
110. Richter, A. and Löscher, W., (+)-WIN-55,212-2, a novel cannabinoid receptor agonist, exerts antidystonic effects in mutant dystonic hamsters, Eur. J. Pharmacol., 264, 371-377, 1994.
111. 9 dopamine neuronal activity in the rat, NeuroReport, 6, 1421-1425, 1995.
112. 9-Tetrahydrocannabinol elicited ipsilateral circling behavior in rats with unilateral nigral lesion, Life Sci., 37, 2181-2185, 1985.
113. Stark, P. and Dews, P. B., Cannabinoids. I. Behavioral effects, J. Pharmacol. Exp. Ther., 214, 124-130, 1980.
114. Souilhac, J., Poncelet, M., Rinaldi-Carmona, M., Le Fur, G., and Soubrié, P., Intrastriatal injection of cannabinoid receptor agonists induced turning behavior in mice, Pharmacol. Biochem. Behav., 51, 3-7, 1995.
115. 9-tetrahydrocannabinol on potassium-evoked release of dopamine in the rat caudate nucleus: an in vivo electrochemical and in vivo microdialysis study, Brain Res., 451, 59-68, 1988.
116. French, E. D., Dillon, K., and Wu, X., Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra, NeuroReport, 8, 649-652, 1997.
117. Rodríguez de Fonseca, F., Del Arco, I., Martin-Calderón, J. L., Gorriti, M. A., and Navarro, M., Role of endogenous cannabinoid system in the regulation of motor activity, Neurobiol. Dis., 5, 483-501, 1998.
118. Goudie, A. J., Animal models of drug abuse and dependence, in Behavioural Models in Psychopharmacology: Theoretical, Industrial, and Clinical Perspectives, Willner, P., Ed., Cambridge University Press, Cambridge, 1991, 453-184.
119. Stellar, J. S. and Rice, M. B., Pharmacological basis of intracranial self-stimulation reward, in The Neuropharmacological Basis of Reward, Liebman, J. M. and Cooper, S. J., Eds., Clarendon Press, Oxford, 1989, 14-65.
120. Carr, G. D., Fibiger, H. C., and Phillips, A. G., Conditioned place preference as a measure of drug reward, in The Neuropharmacological Basis of Reward, Liebman, J. M. and Cooper, S. J., Eds., Clarendon Press, Oxford, 1989, 264-319.
121. Leite, J. R. and Carlini, E. A., Failure to obtain "cannabis-directed behavior" and abstinence syndrome in rats chronically treated with Cannabis sativa extracts, Psychopharmacologia, 36, 133-145, 1974.
122. Harris, R. T., Waters, W., and McLendon, D., Evaluation of reinforcing capability of delta-9-tetrahydrocannabinol in rhesus monkeys, Psychopharmacology, 37, 23-29, 1974.
123. Corcoran, M. and Amit, Z., Reluctance of rats to drink hashish suspensions: free-choice and forced consumption, and the effects of hypothalamic stimulation, Psychopharmacologia, 35, 129-147, 1974.
124. 9-tetrahydrocannabinol as a reinforcer of intravenous self-administration behavior under a second order schedule of drug injection in squirrel monkeys, Behav. Pharmacol., 7(Suppl. 1), 123-124, 1996.
125. Young, A. M., Katz, J. L., and Woods, J. H., Behavioral effects of levonantradol and nantradol in the rhesus monkey, J. Clin. Pharmacol., 21, 348S-360S, 1981.
126. 9-tetrahydrocannabinol and CP 55,940 to maintain intravenous self-administration under a fixed-interval schedule in rhesus monkeys, Behav. Pharmacol., 5, 219-225, 1994.
127. 9-tetrahydrocannabinol: comparison with cocaine, morphine, and food reward, Life Sci., 56, 2073-2080, 1995.
128. Parker, L. A. and Gillies, T., THC-induced place and taste aversion in Lewis and Sprague-Dawley rats, Behav. Neurosci., 109, 71-78, 1995.
129. Sañudo-Peña, M. C., Tsou, K., Delay, E. R., Hohman, A. G., Force, M., and Walker, J. M., Endogenous cannabinoids as an aversive or counter-rewarding system in the rat, Neurosci. Lett., 223, 125-128, 1997.
130. Chaperon, F., Soubrié, P., Puech, A. J., and Thiébot, M. H., Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats, Psychopharmacology, 135, 324-332, 1998.
131. 9-tetrahydrocannabinol, Br. J. Pharmacol., 125, 1567-1577, 1998.
132. Gardner, E. L., Paredes, W., Smith, D., Donner, A., Milling, C., Cohen, D., and Morisson, D., Facilitation of brain stimulation reward by delta-9-tetrahydrocannabinol, Psychopharmacology, 96, 142-144, 1988.
133. Lepore, M., Liu, X., Savage, V., Matalon, D., and Gardner, E. L., Genetic differences in delta 9-tetrahydrocannabinol-induced facilitation of brain stimulation reward as measured by a rate-frequency curve-shift electrical brain stimulation paradigm in three different rat strains, Life Sci., 58, PL365-PL372, 1996.
134. 9-tetrahydrocannabinol by rats, Pharmacol. Biochem. Behav., 11, 737-740, 1979.
135. Sanger, D. J., Drug taking as adjunctive behavior, in Behavioral Analysis of Drug Dependence, Goldberg, S. R. and Stolerman, I. P., Eds., Academic Press, New York, 1986, 123-160.
136. Takahashi, R. N. and Singer, G., Effects of body weight levels on cannabis self-injection, Pharmacol. Biochem. Behav., 13, 877-881, 1980.
137. Takahashi, R. N. and Singer, G., Cross self-administration of delta-9-tetrahydrocannabinol and D-amphetamine in rats, Braz. J. Med. Biol. Res., 14, 395-400, 1981.
138. Martellotta, M. C., Cossu, G., Fattore, L., Gessa, G. L., and Fratta, W., Self-administration of the cannabinoid receptor agonist WIN 55,212-2 in drug naive mice, Neuroscience, 85, 327-330, 1998.
139. George, F. R., Genetic and environmental factors in ethanol self-administration, Pharmacol. Biochem. Behav., 27, 379-384, 1987.
140. Cannon, D. S. and Carrell, L. E., Rat strain differences in ethanol self-administration and taste aversion learning, Pharmacol. Biochem. Behav., 28, 57-63, 1987.
141. Horan, B., Smith, M., Gardner, E. L., Lepore, M., and Ashby, C. R., Jr., (-)-Nicotine produces conditioned place preference in Lewis, but not Fischer 344 rats, Synapse, 26, 93-94, 1987.
142. 9-tetrahydrocannabinol on hypothalamically induced feeding, Psychopharmacology, 103, 172-176, 1991.
143. Chataigneau, T., Félétou, M., Thollon, C., Villeneuve, N., Vilaine, J. P., Duhault, J., and Vanhoutte, P. M., Cannabinoid CB1 receptor and endothelium-dependent hyperpolarization in guinea-pig carotid, rat mesenteric and porcine coronary arteries, Br. J. Pharmacol., 123, 968-974, 1998.
144. Calignano, A., La Rana, G., Makriyannis, A., Lin, S. Y., Beltramo, M., and Piomelli, D., Inhibition of intestinal motility by anandamide, an endogenous cannabinoid, Eur. J. Pharmacol., 340, R7-R8, 1997.
145. Rodríguez de Fonseca, F., Fernández-Ruiz, J. J., Murphy, L., Eldridge, J. C., Steger, R. W., and Bartke, A., Effects of delta-9-tetrahydrocannabinol exposure on adrenal medullary function: evidence of an acute effect and development of tolerance in chronic treatments, Pharmacol. Biochem. Behav., 40, 593-598, 1991.
146. Rodríguez de Fonseca, F., Villanúa, M. A., Munoz, R. M., San-Martin-Clark, O., and Navarro, M., Differential effects of chronic treatment with either dopamine D-1 or D-2 receptor agonists on the acute neuroendocrine actions of the highly potent synthetic cannabinoid HU-210 in male rats, Neuroendocrinology, 61, 714-721, 1995.
147. 9-THC in normal subjects, Psychopharmacology, 76, 245-250, 1982.
148. Gardner, E. L. and Vorel, S. R., Cannabinoid transmission and reward-related events, Neurobiol. Dis., 5, 502-533, 1998.
149. Bienkowski, P., Kuca, P., Piasecki, J., and Kostowski, W., Low dose of ethanol induces conditioned place preference in rats after repeated exposures to ethanol or saline injections, Alcohol Alcohol., 31, 547-553, 1996.
150. Kitaichi, K., Noda, Y., Hasegawa, T., Furukawa, H., and Nabeshima, T., Acute phencyclidine induces aversion, but repeated phencyclidine induces preference in the place conditioning test in rats, Eur. J. Pharmacol., 318, 7-9, 1996.
151. Shoaib, M., Stolerman, I., and Kumar, R., Nicotine-induced place preference following prior nicotine exposure in rats, Psychopharmacology, 113, 445-452, 1994.
152. 1 receptor agonist, Eur. J. Pharmacol., 370, 233-240, 1999.
153. Fratta, W., Martellotta, M. C., Cossu, G., and Fattore, L., Self-administration of the cannabinoid agonist WIN 55212-2 and morphine in mice: evidence for a common neurobiological mechanism, Eur. Neuropsychopharmacol., 8(Suppl. 1), 1998.
154. McGregor, I. S., Topple, A. N., and Hunt, G. E., Beer craving in rats: possible neural substrates, in XXIst CNIP Congress, Glasgow, Scotland, July 12-16, 1998, Abstract PW16080, 443.
155. Gallate, J. E. and McGregor, I. S., The motivation for beer in rats: effects of ritanserin, naloxone and SR 141716, Psychopharmacology, 142, 302-308, 1999.
156. Arnone, M., Maruani, J., Chaperon, F., Thiébot, M. H., Poncelet, M., Soubrié, P., and Le Fur, G., Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors, Psychopharmacology, 132, 104-106, 1997.
157. Colombo, G., Agabio, R., Fà, M., Guano, L., Lobina, C., Loche, A., Reali, R., and Gessa, G. L., Reducing voluntary ethanol intake in ethanol-preferring sP rats by the cannabinoid antagonist SR 141716, Alcohol Alcohol., 33, 126-130, 1998.
158. 9-Tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis, Psychopharmacology, 102, 156-162, 1990.
159. 9-Tetrahydrocannabinol enhances presynaptic dopamine efflux in medial prefrontal cortex, Eur. J. Pharmacol., 190, 259-262, 1990.
160. 9-Tetrahydrocannabinol increases prefrontal cortical catecholaminergic utilization and impairs spatial working memory in the rat: blockade of dopaminergic effects with HA966, Neuropsychopharmacology, 16, 426-432, 1997.
161. 9-tetrahydrocannabinol enhances ventral tegmental somato-dendritic dopamine levels but not forebrain dopamine levels: evidence for local neural action by marijuana's psychoactive ingredient, Brain Res., 621, 65-70, 1993.
162. 9-tetrahydrocannabinol in the nucleus accumbens of rat: an in vivo microdialysis study, Neurosci. Lett., 129, 136-140, 1991.
163. 1 opioid receptor mechanism, Science, 276, 2048-2050, 1997.
164. French, E. D., Delta-9-Tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors, Neurosci. Lett., 226, 159-162, 1997.
165. Gifford, A. N., Gardner, E. L., and Ashby, C. R. J., The effects of intravenous administration of delta-9-tetrahydrocannabinol on the activity of A10 dopamine neurons recorded in vivo in anesthetized rats, Neuropsychobiology, 36, 96-99, 1997.
166. 1 receptors, Eur. J. Pharmacol., 341, 39-44, 1998.
167. Diana, M., Melis, M., and Gessa, G. L., Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids, Eur. J. Neurosci., 10, 2825-2830, 1998.
168. Abel, E. L., Effects of marihuana on the solution of anagrams, memory, and appetite, Nature, 231, 260-261, 1971.
169. Foltin, R. W., Fischman, M. W., and Byrne, M. F., Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory, Appetite, 11, 1-14, 1988.
170. Mattes, R. D., Engelman, K., Shaw, L. M., and Elsohly, M. A., Cannabinoids and appetite stimulation, Pharmacol. Biochem. Behav., 49, 187-195, 1994.
171. Plasse, T. F., Gorter, R. W., Krasnow, S. H., Lane, M., Shepard, K. V., and Wadleigh, R. G., Recent clinical experience with dronabinol, Pharmacol. Biochem. Behav., 40, 695-700, 1991.
172. 9-tetrahydrocannabinol, Behav. Biol., 20, 104-110, 1977.
173. Williams, C. M., Rodgers, P. J., and Kirkham, T. C., Hyperphagia in pre-fed rats following oral delta-9-THC, Physiol. Behav., 65, 343-346, 1998.
174. Graceffo, T. J. and Robinson, J. K., Delta-9-tetrahydrocannabinol (THC) fails to stimulate consumption of a highly palatable food in the rat, Life Sci., 62, PL85-PL88, 1998.
175. 9-tetrahydrocannabinol, Pharmacol. Biochem. Behav., 9, 619-630, 1978.
176. 9-THC-actions by cannabinol and cannabidiol in the rat, Psychopharmacologia, 38, 329-338, 1974.
177. 8-THC) on water intake in water deprived rats: implications for behavioral studies on marijuana compounds, Psychopharmacologia, 30, 315-322, 1973.
178. Sofia, R. D. and Knobloch, L. C., Comparative effects of various naturally occurring cannabinoids on food, sucrose and water consumption by rats, Pharmacol. Biochem. Behav., 4, 591-599, 1976.
179. Milano, W. C., Wid, K. D., Hui, Y., Hubbell, C. K., and Reid, L. D., PCP, THC, ethanol, and morphine and consumption of palatable solutions, Pharmacol. Biochem. Behav., 31, 893-897, 1989.
180. Colombo, G., Agabio, R., Diaz, G., Lobina, C., Reali, R., and Gessa, L. L., Appetite suppression and weight loss after the cannabinoid antagonist SR 141716, Life Sci., 63, PL113-PL117, 1998.
181. 1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset, Behav. Pharmacol., 9, 179-181, 1998.
182. Bizot, J. C., Thiébot, M. H., Le Bihan, C., Soubrié, P., and Simon, P., Effect of imipramine-like drugs and serotonin uptake blockers on delay of reward in rats. Possible implication in the behavioral mechanism of action of antidepressants, J. Pharmacol. Exp. Ther., 246, 1144-1151, 1988.
183. Miller, L. L. and Branconnier, R. J., Cannabis: effects on memory and the cholinergic limbic system, Psychol. Bull., 93, 441-456, 1983.
184. Hall, W. and Solowij, N., Adverse effects of cannabis, Lancet, 352(9140), 1611-1616, 1998.
185. Lyketsos, C. G., Garrett, E., Liang, K. Y., and Anthony, J. C., Cannabis use and cognitive decline in persons under 65 years of age, Am. J. Epidemiol., 149, 794-800, 1999.
186. Lichtman, A. H., Dimen, K. R., and Martin, B. R., Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats, Psychopharmacology, 119, 282-290, 1995.
187. Nakamura, E. M., da Silva, E. A., Concilio, G. V., Wilkinson, D. A., and Masur, J., Reversible effects of acute and long-term administration of delta-9-tetrahydrocannabinol (THC) on memory in the rat, Drug Alcohol Depend., 28, 167-175, 1991.
188. Molina-Holgado, F., Gonzalez, M. I., and Leret, M. L., Effect of delta 9-tetrahydrocannabinol on short-term memory in the rat, Physiol. Behav., 57, 177-179, 1995.
189. Mallet, P. E. and Beninger, R. J., The endogenous cannabinoid receptor agonist anandamide impairs memory in rats, Behav. Pharmacol., 7, 276-284, 1996.
190. Deadwyler, S. A. and Hampson, R. E., Cannabinoids selectively affect processing of information into memory, Behav. Pharmacol., 9(Suppl. 1), S29, 1998.
191. 9-tetrahydrocannabinol or anandamide, Psychopharmacology, 140, 11-19, 1998.
192. Hampson, R. E. and Deadwyler, S. A., Role of cannabinoid receptors in memory storage, Neurobiol. Dis., 5, 474-482, 1998.
193. Evans, E. B. and Wenger, G. R., Effects of drugs of abuse on acquisition of behavioral chains in squirrel monkeys, Psychopharmacology, 107, 55-60, 1992.
194. 9-Tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism, Psychopharmacology, 126, 125-131, 1996.
195. Brodkin, J. and Moerschbaecher, J. M., SR 141716A antagonizes the disruptive effects of cannabinoid ligands on learning in rats, J. Pharmacol. Exp. Ther., 282, 1526-1532, 1997.
196. 2 dopamine receptors, Behav. Pharmacol., 8, 707-712, 1997.
197. Terranova, J.-P., Storme, J.-J., Lafon, N., Pério, A., Rinaldi-Carmona, M., Le Fur, G., and Soubrié, P., Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716, Psychopharmacology, 126, 165-172, 1996.
198. Santucci, V., Storme, J. J., Soubrié, P., and Le Fur, G., Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis, Life Sci., 58, PL103-PL110, 1996.
199. 1 cannabinoid receptor antagonist, SR 141716A, on cognitive performance in intact, brain-damaged and scopolamine-treated rats, Behav. Pharmacol., 9(Suppl. 1), S25, 1998.
200. Mansbach, R. S., Rovetti, C. C., Winston, E. N., and Lowe, J. A., III, Effects of the cannabinoid CB1 receptor antagonist SR 141716A on the behavior of pigeons and rats, Psychopharmacology, 124, 315-322, 1996.
201. Gessa, G. L., Mascia, M. S., Casu, M. A., and Carta, G., Inhibition of hippocampal acetylcholine release by cannabinoids: reversal by SR 141716A, Eur. J. Pharmacol., 327, R1-R2, 1997.
202. 9-tetrahydrocannabinol in rats, Brain Res., 809, 1-4, 1998.
203. Gifford, A. N. and Ashby, C. R., Electrically evoked acetylcholine release from hippocampal slices is inhibited by cannabinoid receptor agonist, WIN-55212-2 and is potentiated by the cannabinoid antagonist, SR-141716A, J. Pharmacol. Exp. Ther., 211, 1431-1436, 1996.
204. Gifford, A. N., Tang, Y., Gatley, S. J., Volkow, N. D., Lan, R., and Makriyannis, A., Effect of the cannabinoid receptor SPECT agent, AM-281, on hippocampal acetylcholine release from rat brain slices, Neurosci. Lett., 238, 84-86, 1997.
205. Cadogan, A. K., Latif, M. L., Alexander, S. P. H., and Kendall, D. A., Evidence that cannabinoids have no effect on acetylcholine release in the rat cerebral cortex, Br. J. Pharmacol., 117S, 316P, 1996.
206. Gessa, G. L., Casu, M. A., Carta, G., and Mascia, M. S., Cannabinoids decrease acetylcholine in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A, Eur. J. Pharmacol., 355, 119-124, 1998.
207. Stella, N., Schweitzer, P., and Piomelli, D., A second endogenous cannabinoid that modulates long-term potentiation, Nature, 388, 773-778, 1997.
208. Bliss, T. V. P. and Collingridge, G. L., A synaptic model of memory: long-term potentiation in the hippocampus, Nature, 361, 31-39, 1993.
209. Collins, D. R., Pertwee, R. G., and Davies, S. N., The action of synthetic cannabinoids on the induction of long-term potentiation in the rat hippocampal slice, Eur. J. Pharmacol., 259, R7-R8, 1994.
210. 1 cannabinoid receptors, Naunyn Schmiedebergs Arch. Pharmacol., 352, 576-579, 1995.
211. Murphy, B. L., Arnsten, A. F. T., Goldman-Rakic, P. S., and Roth, R. H., Increased dopamine turnover in the prefrontal cortex impairs spatial working memory performance in rats and monkeys, Proc. Natl. Acad. Sci. U.S.A., 93, 1325-1329, 1996.
212. 9-tetrahydrocannabinol reduces prefrontal cortical dopamine metabolism in the rat, Neurosci. Lett., 246, 169-172, 1998.
213. File, S. E., The contribution of behavioral studies to the neuropharmacology of anxiety, Neuropharmacology, 26, 877-886, 1987.
214. Rodgers, R. J., Johnson, N. J. T., Carr, J., and Hodgson, T. P., Resistance of experientially-induced changes in murine plus-maze behavior to altered re-test conditions, Behav. Brain Res., 86, 71-77, 1997.
215. Chakrabarti, A., Ekuta, J. E., and Onaivi, E. S., Neurobehavioral effects of anandamide and cannabinoid receptor gene expression in mice, Brain Res. Bull., 45, 67-74, 1998.
216. Rodríguez de Fonseca, F., Carrera, M. R. A., Navarro, M., Koob, G. F., and Weiss, F., Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal, Science, 276, 2050-2054, 1997.
217. Miczek, K. A., Delta-9-tetrahydrocannabinol: antiaggressive effects in mice, rats, and squirrel monkeys, Science, 199, 1459-1461, 1978.
218. Krsiak, M. and Sulcova, A., Differential effects of six structurally related benzodiazepines on some ethological measures of timidity, aggression and locomotion in mice, Psychopharmacology, 101, 396-402, 1990.
219. Sulcova, A., Krsiak, M., and Donat, P., Beta-CCE and FG 7142 increase defensiveness during intraspecies encounters in mice, Psychopharmacology, 108, 205-209, 1992.
220. Olivier, B., Molewijk, E., van Oorschot, R., van der Poel, G., Zethof, T., van der Heyden, J., and Mos, J., New animal models of anxiety, Eur. Neuropsychopharmacol., 4, 93-102, 1994.
221. McGregor, I. S., Dastur, F. N., McLellan, R. A., and Brown, R. E., Cannabinoid modulation of rat pup ultrasonic vocalizations, Eur. J. Pharmacol., 313, 43-49, 1996.
222. Navarro, M., Hernández, E., Muñoz, R. M., del Arco, I., Villanúa, M. A., Carrera, M. R. A., and Rodríguez de Fonseca, F., Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat, NeuroReport, 8, 491-496, 1997.
223. Duffy, A. and Milin, R., Case study: withdrawal syndrome in adolescent chronic cannabis users, J. Am. Acad. Child Adolesc. Psychiatry, 35, 1618-1621, 1996.
224. Jones, R. T., Benowitz, N. L., and Herning, R. I., Clinical relevance of cannabis tolerance and dependence, J. Clin. Pharmacol., 21, 143S-152S, 1981.
225. Wiesbeck, G. A., Schuckit, M. A., Kalmijn, J. A., Tipp, J. E., Bucholz, K. K., and Smith, T. L., An evaluation of the history of a marijuana withdrawal syndrome in a large population, Addiction, 91, 1469-1478, 1996.
226. Fredericks, A. B. and Benowitz, N. L., An abstinence syndrome following chronic administration of delta-9-tetrahydrocannabinol in rhesus monkeys, Psychopharmacology, 71, 201-202, 1980.
227. 9-tetrahydrocannabinol-tolerant rats, Psychopharmacology, 55, 243-249, 1977.
228. Bensusan, A. D., Marihuana withdrawal symptoms, Br. Med. J., 3, 112, 1971.
229. 9-tetrahydrocannabinol: Studies on precipitated and abrupt withdrawal, J. Pharmacol. Exp. Ther., 278, 1290-1295, 1996.
230. Stadnicki, S. W., Schaeppi, U., Rosenkrantz, H., and Braude, M. C., Crude marihuana extract: EEG and behavioral effects of chronic oral administration in rhesus monkeys, Psychopharmacologia, 37, 225-233, 1974.
231. Beardsley, P. M., Balster, R. L., and Harris, L. S., Dependence on tetrahydrocannabinol in rhesus monkeys, J. Pharmacol. Exp. Ther., 239, 311-319, 1986.
232. Wikler, A., Aspects of tolerance to and dependence on cannabis, Ann. N.Y. Acad. Sci., 282, 126-147, 1976.
233. 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist, Eur. J. Pharmacol., 280, R13-R15, 1995.
234. 9-tetrahydrocannabinol, J. Pharmacol. Exp. Ther., 285, 1150-1156, 1998.
235. 9-tetrahydrocannabinol, Eur. J. Pharmacol., 376, 23-26, 1999.
236. Aceto, M. D., Scates, S. M., Radzan, R. K., and Martin, B. R., Anandamide, an endogenous cannabinoid, has a very low physical dependence potential, J. Pharmacol. Exp. Ther., 287, 598-605, 1998.
237. Koob, G. F., Drug addiction: the Yin and Yan of hedonic homeostasis, Neuron, 16, 893-896, 1996.
238. Koob, G. F., Markou, A., Weiss, F., and Schulteis, G., Opponent process and drug dependence: neurobiological mechanisms, Semin. Neurosci., 5, 351-358, 1993.
239. McMillan, D. E., Dewey, W. L., and Harris, L. S., Characteristics of tetrahydrocannabinol tolerance, Ann. N.Y. Acad. Sci., 191, 83-99, 1971.
240. Pertwee, R. G., Stevenson, L. A., and Griffin, G., Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55212-2 and anandamide, Br. J. Pharmacol., 110, 1483-1490, 1993.
241. Welch, S. P., Characterization of anandamide-induced tolerance: comparison to delta(9)-THC-induced interactions with dynorphinergic systems, Drug Alcohol Depend., 45, 39-45, 1997.
242. Oviedo, A., Glowa, J., and Herkenham, M., Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study, Brain Res., 616, 293-302, 1993.
243. 9-tetrahydrocannabinol treatment, Pharmacol. Biochem. Behav., 47, 33-40, 1994.
244. Hsieh, C., Brown, S., Derleth, D., and Mackie, K., Internalization and recycling of the CB1 cannabinoid receptor, J. Neurochem., 73, 493-501, 1999.
245. Romero, J., Garcia-Palomero, E., Castro, J. G., Garcia Gil, L., Ramos, J. A., and Fernández-Ruiz, J. J., Effects of chronic exposure to delta-(9)-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions, Mol. Brain Res., 46, 100-108, 1997.
246. Romero, J., Berrendero, F., Manzanares, J., Perez, A., Corchero, J., Funtes, J. A., Fernández-Ruiz, J. J., and Ramos, J. A., Time-course of the cannabinoid receptor downregulation in the adult rat brain caused by repeated exposure to delta-9-tetrahydrocannabinol, Synapse, 30, 298-308, 1998.
247. 35S]GTPgammaS binding and cannabinoid receptor mRNA levels in several brain structures of adult male rats chronically exposed to R-methanandamide, Neurochem. Int., 34, 473-482, 1999.
248. 9-tetrahydrocannabinol, Pharmacol. Biochem. Behav., 51, 731-737, 1995.
249. 9-THC without alteration of cannabinoid receptor binding or mRNA levels in whole brain, Pharmacol. Biochem. Behav., 46, 575-579, 1993.
250. 9-THC-induced antinociceptive tolerance, Pharmacol. Biochem. Behav., 59, 399-404, 1998.
251. Stewart, J. and Badiani, A., Tolerance and sensitization to the behavioral effects of drugs, Behav. Pharmacol., 4, 289-312, 1993.
252. 9-tetrahydrocannabinol treatment induced sensitization to the psychomotor effects of amphetamine in rats, Eur. J. Pharmacol., 365, 133-142, 1999.
253. Anthony, J. C., Warner, L. A., and Kessler, R. C., Comparative epidemiology of dependence on tobaco, alcohol, controlled substances and inhalents: basic findings from the National Comorbidity Survey, Exp. Clin. Psychopharmacol., 2, 244-268, 1994.
254. Crowley, T. J., Macdonald, M. J., Whitmore, E. A., and Mikulich, S. K., Cannabis dependence, withdrawal, and reinforcing effects among adolescents with conduct symptoms and substance use disorders, Drug Alcohol Depend., 50, 27-37, 1998.
255. 9-THC training dose as a determinant for (R)-methanandamide generalization in rats, Psychopharmacology, 140, 519-522, 1998.
256. 9-THC), and other drugs, Psychopharmacologia, 40, 1-16, 1974.
257. Wiley, J. L., Barrett, R. L., Lowe, J., Balster, R. L., and Martin, B. R., Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats, Neuropharmacology, 34, 669-676, 1995.
258. 9-tetrahydrocannabinol in rats and rhesus monkeys, J. Pharmacol. Exp. Ther., 275, 1-6, 1995.
259. Pério, A., Rinaldi-Carmona, M., Maruani, J., Barth, F., Le Fur, G., and Soubrié, P., Central mediation of the cannabinoid cue: activity of a selective CB1 antagonist, SR 141716A, Behav. Pharmacol., 7, 65-71, 1996.
260. Wiley, J. L., Ryan, W. J., Razdan, R. J., and Martin, B. R., Evaluation of cannabimimetic effects of structural analogs of anandamide, Eur. J. Pharmacol., 355, 113-118, 1998.
261. Wiley, J. L., Golden, K. M., Ryan, W. J., Balster, R. L., Razdan, R. K., and Martin, B. R., Evaluation of cannabimimetic discriminative stimulus effects of anandamide and methylated fluoroanandamide in rhesus monkeys, Pharmacol. Biochem. Behav., 58, 1139-1143, 1997.
262. 9-THC in a drug-discrimination procedure, Exp. Clin. Psychopharmacol., 5, 195-202, 1997.
263. Romero, J., de Miguel, R., García-Palomero, E., Fernández-Ruiz, J. J., and Ramos, J. A., Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function, Brain Res., 694, 223-232, 1995.
264. Barg, J., Fride, E., Hanus, L., Levy, R., Matus-Leibovitch, N., Heldman, E., Bayewitch, M., Mechoulam, R., and Vogel, Z., Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides, Eur. J. Pharmacol., 287, 145-152, 1995.
265. Murillo-Rodríguez, E., Sánchez-Alavez, M., Navarro, L., Martínez-González, D., Drucker-Colín, R., and Prospéro-García, O., Anandamide modulates sleep and memory in rats, Brain Res., 812, 270-274, 1998.
266. Fride, E., Ben-Shabat, S., and Mechoulam, R., Pharmacology of endogenous and exogenous cannabinoid receptor agonists, Behav. Pharmacol., 9(Suppl. 1), S39, 1998.
267. Schlicker, E., Timm, J., Zentner, J., and Göthert, M., Cannabinoid CB1 receptor-mediated inhibition of noradrenaline release in the human and guinea-pig hippocampus, Naunyn Schmiedebergs Arch. Pharmacol., 356, 583-589, 1997.
268. McGregor, I. S., Saharov, T., Dielenberg, R. A., and Arnold, J. C., The effects of cannabinoids on beer and sucrose consumption in rats, in Symposium on the Cannabinoids, Burlington, Vermont, U.S.A., 1997, International Cannabinoids Research Society.
269. Bouaboula, M., Perrachon, S., Milligan, L., Canat, X., Rinaldi-Carmona, M., Potier, M., Barth, F., Calandra, B., Pecceu, F., Lupker, J., Maffrand, J. P., Le Fur, G., and Casellas, P., A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions, J. Biol. Chem., 272, 22330-22339, 1997.
270. 2 receptors, Br. J. Pharmacol., 124, 619-622, 1998.
271. 2+ currents by reversal of tonic CB1 cannabinoid receptor activity, Mol. Pharmacol., 54, 1064-1072, 1998.
272. Pertwee, R. G., Medical use of cannabinoids: the way forward, Addiction, 94, 317-320, 1999.
273. Sussman, S., Stacy, A. W., Dent, C. W., Simon, T. R., and Johnson, C. A., Marijuana use: current issues and new research directions, J. Drug Issues, 26, 695-733, 1996.
274. Abrahamov, A., Abrahamov, A., and Mechoulam, R., An efficient new cannabinoid antiemetic in pediatric oncology, Life Sci., 56, 2097-2102, 1995.
275. Fride, E. and Mechoulam, R., Developmental aspects of anandamide: ontogeny of response and prenatal exposure, Psychoneuroendocrinology, 21, 157-172, 1996.
276. Petitet, F. and Imperato, A., The therapeutic applications of cannabinoid agonists and antagonists, Emerging Drugs, 3, 39-53, 1998.
277. Consroe, P., Brain cannabinoid systems as targets for therapy of neurological disorders, Neurobiol. Dis., 5, 534-551, 1998.
278. Russo, E., Cannabis for migraine treatment: the once and future prescription? An historical and scientific review, Pain, 76, 3-8, 1998.
279. Tien, A. Y. and Anthony, J. C., Epidemiological analysis of alcohol and drug use as risk factor for psychotic experience, J. Nerv. Ment. Dis., 178, 473-480, 1990.
280. Emrich, H. M., Leweke, F. M., and Schneider, U., Towards a cannabinoid hypothesis of schizophrenia: Cognitive impairments due to dysregulation of the endogenous cannabinoid system, Pharmacol. Biochem. Behav., 56, 803-807, 1997.
281. D'Souza, D. C., Abi-Saab, W., Belger, A., Madonick, S., Larvey, K., Cassello, K., Sernyak, M., and Krystal, J., Cannabinoid sensitivity in schizophrenia: Evidence from a study with intravenous tetrahydrocannabinol in schizophrenics and controls, in XXIst CNIP Congress, Glasgow, Scotland, 1998, Abstract NRT008, 117.
282. Peng, R. Y., Mansbach, R. S., Braff, D. L., and Geyer, M. A., A D2 dopamine receptor agonist disrupts sensorimotor gating in rats. Implications for dopaminergic abnormalities in schizophrenia, Neuropsychopharmacology, 3, 211-218, 1990.
283. Poncelet, M., Barnouin, M. C., Brelière, J. C., Le Fur, G., and Soubrié, P., Blockade of cannabinoid (CB1) receptors by SR 141716 selectively antagonizes drug-induced reinstatement of exploratory behavior in gerbils, Psychopharmacology, 144, 144-150, 1999.